AG真人官方

atai Life Sciences N.V. (Nasdaq: ATAI) filed an 8-K announcing two material developments:

1. $50 million PIPE financing: On 1 July 2025 the company signed Subscription Agreements with several investors鈥攊ncluding Apeiron Investment Group, the family office of co-founder Christian Angermayer鈥攖o sell 18,264,840 ordinary shares at $2.19 and issue a pre-funded warrant for 4,566,210 shares at a $0.01 exercise price (also priced at $2.19 per underlying share). Closing is targeted for Q3-25 and is subject to customary conditions, notably expiration of the Hart-Scott-Rodino waiting period related to Apeiron鈥檚 participation. Either side may terminate if the deal is not completed by 1 Nov 2025. Securities are being sold under Section 4(a)(2) and will be registered for resale under a new Registration Rights Agreement. Management expects the additional capital to extend the company鈥檚 cash, short-term securities and public equity runway into H2-2027.

2. Positive Phase IIb data for BPL-003 in treatment-resistant depression (TRD): Beckley Psytech鈥攃urrently subject to an acquisition agreement with ATAI鈥攔eported that a single 12 mg intranasal dose of BPL-003 produced a mean 11.1-point reduction in MADRS versus 5.8 for the 0.3 mg comparator (p = 0.0038) at Day 29. The 8 mg dose yielded a 12.1-point reduction (p = 0.0025). Statistically significant effects emerged by Day 2 and remained durable through Day 57. Safety was acceptable, with >99% of adverse events mild or moderate and no suicide-related signals. The company plans to advance the 8 mg dose to Phase III.

• Use of proceeds: working capital and advancement of ATAI鈥檚 clinical pipeline; funds will not be used to finance the pending Beckley acquisition.
• Placement agents: TD Securities, Leerink Partners, Guggenheim Securities and Berenberg.
• Dilution impact: Potential issuance of ~22.8 million new shares (inclusive of warrant) before registration.

Overall, the financing strengthens ATAI鈥檚 balance sheet while positive clinical data from its pending target bolsters the strategic rationale for the Beckley acquisition.

Packaging Corporation of America (NYSE: PKG) filed an 8-K to disclose a definitive agreement to acquire Greif, Inc.鈥檚 containerboard business for $1.8 billion in cash. The transaction was announced on 1 July 2025 and is supported by a press release (Ex. 99.1) and an investor slide deck (Ex. 99.2) now available on PCA鈥檚 website. Because the disclosure is furnished under Item 7.01 鈥� Regulation FD, it is not deemed 鈥渇iled鈥� for liability purposes under the Exchange Act.

The filing offers no financial statements, pro-forma data, or financing details, but it confirms:

• Scope: Entire containerboard division of Greif, expanding PCA鈥檚 core corrugated packaging platform.
• Price: All-cash consideration of $1.8 billion.
• Materials Available: Press release and slide presentation outlining strategic rationale (furnished, not filed).

The acquisition signals a major capital deployment aimed at strengthening PCA鈥檚 market position in containerboard. Investors should monitor forthcoming filings for financing structure, regulatory approvals, expected closing timeline, and any pro-forma EBITDA or synergy forecasts, none of which are included in this 8-K.

Form 4 overview: ATAI Life Sciences N.V. filed a Form 4 on 27 June 2025 detailing a new option grant to director Andrea Heslin Smiley.

The award covers 103,000 options on ATAI common shares at an exercise price of $2.25, granted 26 June 2025. The option vests on the earlier of (i) the day before ATAI鈥檚 next annual shareholder meeting or (ii) 26 June 2026, and expires 26 June 2035. No common shares were acquired or disposed; the transaction only increases the director鈥檚 derivative holdings.

Following the grant, Smiley directly owns 103,000 derivative securities and no change is reported in non-derivative share ownership. The filing appears to be routine director compensation, carries no indication of a Rule 10b5-1 trading plan, and provides limited insight into ATAI鈥檚 operational or financial performance.

ATAI Life Sciences N.V. 鈥� Key details from Form 4

Director Amir H. Kalali filed a Form 4 on 27 June 2025 reporting the grant of a non-derivative stock option covering 103,000 common shares of ATAI Life Sciences N.V. The option was issued on 26 June 2025 with an exercise price of $2.25 per share and will vest on the earlier of (i) the day before ATAI鈥檚 next annual meeting or (ii) 26 June 2026. The option expires on 26 June 2035. After the transaction, Kalali holds 103,000 derivative securities directly. No open-market purchases or sales of ATAI shares were reported in this filing.

The filing represents a routine equity incentive award designed to align the director鈥檚 long-term interests with shareholders. Because the option is not yet exercised, there is no immediate change to share count or insider ownership of outstanding common shares.

ATAI Life Sciences N.V. (ATAI) 鈥� Form 4 insider filing

Director Sabrina Martucci Johnson reported the grant of 103,000 stock options on 26 June 2025. The options carry a strike price of $2.25 and expire on 26 June 2035. Vesting occurs on the earlier of the day before ATAI鈥檚 next annual meeting or 26 June 2026. Following this transaction Ms. Johnson beneficially owns 103,000 derivative securities, held directly. No non-derivative share transactions were disclosed.

The filing was signed by attorney-in-fact Ryan Barrett on 27 June 2025. No 10b5-1 trading plan box was checked, and the director remains subject to Section 16 reporting obligations.

ATAI Life Sciences N.V. (ATAI) Form 4 highlights: on June 26, 2025 director John Francis Hoffman was granted a stock option covering 206,000 common shares at an exercise price of $2.25 per share.

The option vests 33% on June 26, 2026; the remaining 67% vests in 24 equal monthly installments, reaching full vesting on June 26, 2028. After the award, Hoffman beneficially owns 206,000 derivative securities; no non-derivative share transactions were reported.

The filing, signed by attorney-in-fact Ryan Barrett on June 27, 2025, reflects routine director compensation and does not disclose any sales or purchases of existing shares.

Form 4 filing overview: ATAI Life Sciences N.V. reported that director Laurent Fischer was granted a new option award on 26 June 2025.

Key details:

• Derivative security: Stock option on ATAI common shares
• Quantity granted: 103,000 options
• Exercise price: $2.25 per share
• Expiration: 26 June 2035
• Vesting: Options vest on the earlier of (i) the day before the company鈥檚 next annual meeting or (ii) 26 June 2026.
• Ownership status: Following this transaction, the reporting person beneficially owns 103,000 derivative securities, held directly.

The filing represents a routine equity compensation grant to a non-executive director and does not disclose any purchase or sale of ATAI common shares. No cash consideration was exchanged at grant (price of derivative security recorded as $0), indicating a standard incentive award. The disclosure offers no new information on company operations, earnings, or strategic developments.

Form 4 snapshot 鈥� ATAI Life Sciences N.V. (NASDAQ: ATAI)

Director Dr. Scott Braunstein reported the grant of 103,000 non-qualified stock options on 26 Jun 2025 at an exercise price of $2.25 per common share. The options expire on 26 Jun 2035 and will vest in full on the earlier of (i) the day prior to the company鈥檚 next annual general meeting or (ii) 26 Jun 2026, providing a 12-month maximum vesting horizon. Following the award, Dr. Braunstein now beneficially owns 103,000 derivative securities; no common shares were bought or sold, and no other transactions were reported.

The filing represents routine director compensation under the company鈥檚 equity incentive plan. As the grant is at-the-money (current market price 鈮� exercise price) and totals roughly <0.1% of shares outstanding, it has minimal dilution impact. Nonetheless, the award aligns the director鈥檚 incentives with long-term shareholder value, signalling continued board engagement.

Form 4 filing overview: On 06/27/2025 ATAI Life Sciences N.V. (symbol: ATAI) reported a change in beneficial ownership by Christian Angermayer, who is both a Director and 10% owner.

Key transaction: On 06/26/2025 the insider received a stock option covering 103,000 common shares at an exercise price of $2.25 per share. The award was coded "A" (grant or award) and is held directly by the reporting person.

Vesting & expiration: The option vests on the earlier of (i) the day before ATAIs next annual shareholder meeting or (ii) 06/26/2026, and it expires on 06/26/2035. No deemed execution date or other conditions were noted.

Post-transaction holdings: Following the grant, Mr. Angermayer beneficially owns 103,000 derivative securities (stock options). Table I shows no non-derivative share acquisitions or dispositions.

Investor take-away: The filing reflects a routine equity incentive grant rather than an open-market purchase or sale, so it carries limited immediate signalling value. The award incrementally increases potential dilution but has no direct impact on ATAIs cash position or current share count.